For the survey, the research and development nonprofit asked 229 pharmaceutical and life science leaders about their attitudes toward AI.
Here are three survey insights respondents shared:
1. The majority of respondents — 69 percent — reported their organization uses AI, whether in the form of machine learning, deep learning or through chatbots. Nineteen percent of respondents said they plan to use AI within the next year, while 12 percent said they have no plans to use AI.
2. Of those already using AI within their organizations, 21 percent indicated the AI projects were not yet providing meaningful outcomes. Another 21 percent said they “didn’t know” if these projects were delivering meaningful outcomes.
3. When asked which sectors they planned to collaborate on for AI development in the next 18 months, most respondents indicated either a technology or data provider (40 percent), followed by stakeholders in healthcare (22 percent) or academia (15 percent).
“This survey shows interest in AI remains strong, but there is still a challenge with moving past the hype to a realty where AI is delivering insights with the power to truly augment researchers’ work,” Steve Arlington, PhD, president of The Pistoia Alliance, said in a June 7 statement.
More articles on health IT:
UC San Diego Health joins OpenNotes: 4 things to know
Former IBM security exec joins Protenus as CFO: 3 things to know
Congressional leaders to HHS: It’s unclear if troubled cybersecurity center ‘still exists’
